Revelation Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a REVB research report →
Price Chart
About the company
Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease.
- CEO
- James Rolke
- IPO
- 2020
- Employees
- 8
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on REVB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.18M
- P/E
- -0.15
- Fwd P/E
- 0.31
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.41
- EV/EBITDA
- 0.60
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -100.20%
- ROIC
- -104.28%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-27,058+3.1%
- Op Income
- $-9,070,814
- Net Income
- $-8,913,649+40.7%
- EPS
- $-23.95+72.7%
- OCF Growth
- +54.9%
- FCF Growth
- +54.9%
- 52W High
- $11.72
- 52W Low
- $0.88
- 50D MA
- $1.06
- 200D MA
- $1.92
- Beta
- -0.17
- RSI (14)
- 48
- Avg Volume
- 43.60K
No earnings-call transcripts are available for REVB yet.
- Free Float
- 74.1%
- Shares Outstanding
- 3.91M
- Float Shares
- 2.89M
of shares held by institutions
13 13F filers
Buy/sell ratio 6.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for REVB, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Pat ToomeySenate · PA | Sell | May 16, 18 | Filing → |
| Pat ToomeySenate · PA | Sell | Jun 6, 18 | Filing → |
| Pat ToomeySenate · PA | Sell | Jun 25, 18 | Filing → |
| Pat ToomeySenate · PA | Sell | Mar 22, 18 | Filing → |
| Pat ToomeySenate · PA | Sell | Jan 8, 18 | Filing → |
| Pat ToomeySenate · PA | Sell | Jan 30, 18 | Filing → |
| Pat ToomeySenate · PA | Sell | Feb 8, 18 | Filing → |
| Pat ToomeySenate · PA | Sell | Apr 30, 18 | Filing → |
| Pat ToomeySenate · PA | Sell | Jul 27, 18 | Filing → |
| Pat ToomeySenate · PA | Sell | Jul 27, 18 | Filing → |
| Pat ToomeySenate · PA | Sell | Jul 31, 19 | Filing → |
| Pat ToomeySenate · PA | Sell | Dec 7, 17 | Filing → |
| Pat ToomeySenate · PA | Sell | Nov 30, 17 | Filing → |
| Pat ToomeySenate · PA | Sell | Nov 17, 17 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 17, 26 | Rolke James | other | 208,076 |
| Aug 17, 26 | Chawla Lakhmir S | other | 32,011 |
| Aug 17, 26 | Zygmont Chester Stanley III | other | 208,073 |
| Aug 17, 26 | Zygmont Chester Stanley III | other | 208,073 |
| Aug 17, 26 | Zygmont Chester Stanley III | other | 208,073 |
| Aug 17, 26 | ROPER JESS | other | 32,011 |
| Aug 17, 26 | CARVER JENNIFER | other | 32,011 |
| Apr 30, 26 | Rolke James | other | 10,115 |
| Apr 30, 26 | Zygmont Chester Stanley III | other | 13,285 |
| Feb 3, 26 | ROPER JESS | other | 1,591 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our REVB coverage
Recent articles, reports, and earnings notes.
No research on REVB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate REVB report →Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study
businesswire.com · Aug 19
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026
accessnewswire.com · Aug 6
Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury
accessnewswire.com · Aug 3
Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
accessnewswire.com · Jul 21
Revelation Biosciences Announces Adoption of Stockholder Rights Plan
accessnewswire.com · Jul 10
Revelation Biosciences Expands Acute Kidney Injury Advisory Board
accessnewswire.com · Jun 1
Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders
accessnewswire.com · May 11
Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026
accessnewswire.com · May 7
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.